Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update

摘要

Comparison of cardiovascular outcomes in SGLT2i CVOTs. Direct comparison of studies should be interpreted with caution because of differences in study design, populations and methodology. Major adverse cardiac event (MACE) outcomes. Cardiovascular death outcomes. Hospitalization for heart failure outcomes. MRF multiple risk factors, eCVD established cardiovascular disease. * value for interaction. Kidney outcomes in SGLT2 inhibitor outcomes trials. *Accompanied by eGFR ≤ 45 ml/min/1.73 m . Nominal values. Sustained for at least 28 days. eGFR estimated glomerular filtration rate, ESKD end-stage kidney disease, ESRD end-stage renal disease, NR not reported, PY patient-years, RRT renal replacement therapy, SGLTi sodium/glucose cotransporter 2 inhibitor, T2DM type 2 diabetes mellitus